Loading...
•
Sep 30, 2024
Wave Life Sciences Q3 2024 Earnings Report
Announced third quarter 2024 financial results and provided a business update.
Key Takeaways
Wave Life Sciences reported positive clinical updates across DMD and AATD, achieved first-ever RNA editing in humans, and advanced its pipeline. The company's cash runway is expected into 2027.
Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 in alpha-1 antitrypsin deficiency.
WVE-007 clinical trial on track for 1Q 2025, with preclinical data supporting monotherapy or synergistic use with GLP-1s.
Received supportive initial feedback from FDA on WVE-003, with IND submission expected in 2H 2025.
Delivered positive interim data from FORWARD-53 study of WVE-N531; expect feedback on a pathway to accelerated approval from regulators in 1Q 2025.
Wave Life Sciences
Wave Life Sciences
Forward Guidance
Wave Life Sciences anticipates several milestones across its pipeline, including clinical trial initiations, data readouts, and regulatory feedback.
Positive Outlook
- WVE-007 clinical trial initiation in 1Q 2025.
- Delivery of complete 48-week FORWARD-53 data in 1Q 2025.
- Feedback from regulators on a pathway to accelerated approval for WVE-N531 in 1Q 2025.
- IND submission for WVE-003 expected in 2H 2025.
- Selection of clinical candidates for PNPLA3, LDLR and APOB in 2025.